HSCT, or hematopoietic stem cell transplantation, is an intensive treatment for multiple sclerosis that wipes out the faulty immune system attacking the brain and spinal cord, then rebuilds it from scratch using the patient’s own stem cells. It’s sometimes called an “immune reboot.” In clinical studies, 72% of patients showed no evidence of disease activity two years after treatment, and the procedure has outperformed some of the strongest MS drugs available. It is not a first-line therapy, though. HSCT is typically reserved for people with aggressive relapsing-remitting MS who haven’t responded well to standard medications.
How the Immune Reboot Works
In MS, certain immune cells mistakenly attack the protective coating around nerve fibers in the brain and spinal cord. Standard MS drugs work by dampening or redirecting the immune system while it’s still running. HSCT takes a fundamentally different approach: it destroys the immune system entirely, then regrows it from a clean starting point.
The version used for MS is autologous, meaning the stem cells come from the patient’s own body rather than a donor. Before the immune system is destroyed, blood-forming stem cells are collected and frozen. After intensive chemotherapy eliminates the existing immune system, those stored cells are infused back into the bloodstream. They migrate to the bone marrow and begin producing a brand-new set of immune cells, one that, in most cases, no longer attacks the nervous system.
The Four Stages of Treatment
HSCT is a multi-week process broken into distinct phases, each with its own demands on the body.
Mobilization and harvesting comes first. You receive medications that coax stem cells out of the bone marrow and into the bloodstream, where they can be collected through a process similar to blood donation. The collected cells are frozen and stored until needed.
Conditioning is the hardest part. You’re admitted to the hospital and given high-dose chemotherapy to destroy the existing immune system. Conditioning regimens vary in intensity. High-intensity protocols are more effective at eliminating disease but carry greater toxicity, while low-intensity ones have higher failure rates. Most centers use intermediate-intensity regimens that balance effectiveness with safety.
Stem cell infusion and recovery from low blood counts follows conditioning. The frozen stem cells are thawed and infused intravenously. For the next 10 to 14 days, your blood counts drop to dangerously low levels because the old immune system has been destroyed and the new one hasn’t formed yet. During this period you’ll need blood and platelet transfusions, antibiotics, antiviral medications, and antifungal drugs to prevent infections. Neutrophil counts, a key marker of immune defense, typically begin recovering around day 11.
Immune reconstitution is the months-long process of the new immune system maturing. Although you’ll leave the hospital once blood counts stabilize, full immune recovery takes considerably longer. During this period you remain more vulnerable to infections, particularly reactivation of dormant viruses like herpes and hepatitis B.
Who Gets the Best Results
HSCT works best for a specific profile of MS patient. The strongest outcomes have been seen in people under 45 with relapsing-remitting MS, a disease duration of five years or less from diagnosis, and recent inflammatory activity on MRI. In studies focusing on this group, researchers observed near-complete prevention of disability progression and, in many cases, actual improvement in disability levels.
People with progressive MS or those who have already accumulated significant disability tend to benefit less. This makes sense biologically: HSCT targets inflammation, which drives relapsing-remitting disease, but it cannot repair nerve damage that has already occurred. The earlier in the disease course HSCT is performed, the less irreversible damage has built up.
Aggressive or highly active MS, estimated to affect roughly 4 to 14% of people with the disease, is the primary population being treated. Characteristics include frequent relapses, rapid accumulation of neurological problems, and failure to respond to conventional disease-modifying therapies.
How HSCT Compares to MS Drugs
A single-center cohort study comparing HSCT head-to-head with two of the most powerful MS medications found that the transplant came out ahead on key measures. Over five years, patients who received HSCT had an annualized relapse rate of 0.026, compared to 0.087 for those on alemtuzumab. That translates to roughly one relapse every 38 years versus one every 11 years. New brain lesion activity on MRI was also significantly lower in the HSCT group.
Against ocrelizumab, another top-tier drug, HSCT showed a significantly lower relapse rate over three years (0.028 vs. 0.073). New MRI activity, however, was nearly identical between the two groups at 3 years, with 93% of patients in both groups remaining free of new lesions. The key difference is that HSCT is a one-time treatment, while ocrelizumab requires ongoing infusions every six months indefinitely.
Long-term Effectiveness
At two years, 72% of HSCT patients showed no evidence of disease activity, meaning no relapses, no new brain lesions, and no disability progression. By five years, that figure dropped to about 48.5%, which reflects the reality that some patients do experience disease return over time.
Longer follow-up data, with a median of 11 years, confirms that HSCT durably reduces relapses and slows disability progression. In one long-term study, disease reappeared anywhere from 7 months (in patients who received lower-intensity conditioning) to nearly 10 years (with intermediate-intensity regimens). At the final check-in, two patients had improved disability scores, two were stable, and five had worsened, though none by more than a modest amount. These numbers are small but suggest that HSCT is not a guaranteed permanent cure. Some people may eventually need additional treatment.
Risks and Side Effects
HSCT is the most aggressive treatment option for MS, and it carries real risks. The period of severely suppressed blood counts after conditioning is the most dangerous phase. Infections are the primary concern, since the body has essentially no immune defense during the 10 to 14 days before engraftment. Patients need central line access for chemotherapy, fluids, transfusions, and medications, and that line itself can become a source of infection if not meticulously maintained.
Fertility is a major consideration. More than 90% of women who undergo myeloablative conditioning, the type of high-dose chemotherapy used in HSCT, experience ovarian failure. For women of reproductive age, fertility preservation options like egg freezing should be discussed before starting treatment.
In the months following transplant, reactivation of latent viruses is common. Cytomegalovirus, hepatitis B, and various herpes viruses can flare in the immunocompromised state. Ongoing monitoring and preventive antiviral medications help manage this risk during the reconstitution period.
Treatment-related mortality has decreased substantially as centers have gained experience and shifted toward intermediate-intensity conditioning regimens. Early studies reported higher death rates, but modern protocols at experienced transplant centers have brought this risk down significantly. The choice of conditioning intensity directly affects the balance between effectiveness and safety.
What Recovery Looks Like
The inpatient stay covers the conditioning and engraftment phases, typically lasting several weeks. Once neutrophil counts recover, usually around 11 days after the stem cell infusion, the immediate danger period passes and discharge becomes possible.
Recovery after leaving the hospital is gradual. Your immune system will be immature for months, meaning you’ll need to avoid crowds, sick contacts, and certain foods that carry infection risk. Vaccinations given before the transplant are wiped out by the chemotherapy, so you’ll need to be re-vaccinated on a schedule determined by your transplant team, typically starting several months after the procedure.
Many patients report feeling worse before they feel better. The chemotherapy itself causes fatigue, nausea, and general debility that can take weeks to months to fully resolve. Neurological improvement, when it happens, tends to be slow, unfolding over months to years as the new immune system stops the inflammatory damage and the nervous system has a chance to heal what it can.